Praxis Precision Medicines, Inc. announced on June 29, 2026, that the FDA has extended the review period for its relutrigine New Drug Application (NDA) for treating SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) by three months. The updated PDUFA target action date is now December 27, 2026, following the FDA's classification of the Company's additional sensitivity analyses as a
